CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A prospective study of the safety and efficacy of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 19];7(2):s174. Available from: https://skin.dermsquared.com/skin/article/view/1998